USPTO 2015–2025 USPTO PatentsView US Corporation

Evoke Pharma, Inc.

USPTO PatentsView assignee record - 7 granted patents across 4 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

RSS updates for this company

The verdict

According to USPTO PatentsView, Evoke ranks #35,252 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 4 technology areas.

#35,252
of 49,997 US assignees by volume
Top 24%
by Innovation Score (45.1/100)
18.1
avg claims per patent

USPTO PatentsView assignee plate

Corpus R35252 · US Corporation #35,252 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 7 grants
  • MID-PACK #35,252/49,997
  • PHOTO-FINISH Evac OY
  • CPC-NARROW A61K · 4 areas
  • INNOV-PAR 45.1/100
  • CLAIMS-RICH 18.1 claims/avg
  • TYPE-USCORP US Corporation
  • SPAN-YRS 2021–2025 · 5y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Evac OY (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Evoke’s 45.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Evoke

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Evoke's Innovation Score is 45.1/100 (top 24% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Evoke?

Each dot is one of Evoke’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Evoke’s own 18.1 claims/patent is ABOVE the 10.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Evoke vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 6.97.07.077.07.07.1 05101520 Granted patents (volume) Avg claims / patent Evac OY - 7, 11Evac OYEvergreen Land Limited - 7, 4.29Evergreen LandEvergreen Packaging LLC - 7, 15.29Evergreen Packagi…EVO Inventions LLC - 7, 4.71EVO InventionsEvoko Unlimited AB - 7, 1Evoko Unlimited ABEvolv, LLC - 7, 10.43EvolvExergy Power Systems, Inc. - 7, 13.43Exergy Power Syst…Exquadrum, Inc. - 7, 14.57ExquadrumEvoke Pharma, Inc. - 7, 18.14Evoke Pharma
Evoke vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Evoke's grants concentrate

Evoke Pharma, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2023 (2 grants) versus a trough of 1 in 2021. By volume, Evoke sits between Evac OY and Exquadrum, Inc..

Evoke's three-year grant acceleration

Evoke Pharma, Inc. shows 3 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Evoke's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Evoke holds 7 patents at rank #35,174, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Evoke

By rank, the assignees closest to #35,174 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Evoke's primary technology class.

Evoke's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

45 Top 24% higher than 76% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 2021202220232025 3
USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table
Evoke Pharma, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2021 1 14.3%
2022 1 14.3%
2023 2 28.6%
2025partial year 3 42.9%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Evoke Pharma, Inc.'s patent record in context - here's where to go next.

  • Evoke Pharma, Inc.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 100% of its portfolio - see every assignee active in that class. Explore A61K
  • Ranked #35,252 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Evoke Pharma, Inc. against Evac OY, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 45.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.